Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Abstract Background Type 2 diabetes mellitus (T2DM) is characterized by systemic metabolic abnormalities and the development of micro- and macrovascular complications, resulting in a shortened life expectancy. A recent cardiovascular (CV) safety trial, the EMPA-REG OUTCOME trial, showed that empagli...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke R. Shima, Toshinari Takamura, Yasushi Matsuzawa, Kazuo Kimura, Masashi Sakuma, Jun-ichi Oyama, Teruo Inoue, Yukihito Higashi, Shinichiro Ueda, Koichi Node, On Behalf of the EMBLEM Trial Investigators
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Cardiovascular Diabetology
Subjects:
Empagliflozin
Endothelial function
Reactive hyperemia peripheral arterial tonometry (RH-PAT)
Sodium glucose cotransporter 2 (SGLT2) inhibitor
Type 2 diabetes mellitus (T2DM)
Online Access:http://link.springer.com/article/10.1186/s12933-017-0532-8

Internet

http://link.springer.com/article/10.1186/s12933-017-0532-8

Similar Items